ClinicalTrials.gg
CompletedNCT05111912Updated Aug 21, 2023

Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity

A Phase 2 interventional study of XW003 and Saxenda in Obesity, sponsored by Sciwind Biosciences APAC CO Pty. Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by Sciwind Biosciences APAC CO Pty. Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.

Enrollment
79th of 168
206 · median 184
Started
2021
with 10 others
Phase 2
27 of 187
5 open now
Registered
86th of 187
by date

Among the 187 studies in Obesity with a site in Australia, this one is the 79th largest by enrollment of the 168 interventional ones that give a count, is one of 11 that started in 2021, is one of 27 in phase 2, and was the 86th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

56 of the 187 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Obesity with a site in Australia, or all of them as a file.
02

Study summary

XW003 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.

Read the detailed description

The study treatment period for 4 groups in the study will be divided into the four Titration Treatment periods and one Core Treatment period. The overall duration of the study treatment for each group will be 26 weeks. The duration of Titration Treatment will be up to 14 weeks for the three groups of XW003 treatment but 4 weeks for Saxenda group.

Approximately 250 participants who are adults with obesity, in the absence of type 2 or any other type of diabetes, are planned to be screened. Based on a 20% screening failure rate, a total of 200 participants are expected to be enrolled for the four groups.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for this study, a participant has to meet all of the following inclusion criteria:

  1. Male or female, aged 18 to 70 years (inclusive at the time of );
  2. Participants must have a ≥ 30.0 kg/m2 and ≤40.0 kg/m2 at Screening;
  3. Participants must have a stable body weight for at least 3 months prior to Screening (\<5% change, self-reported);
  4. Participants must have (HbA1c) level \<6.5% at Screening;
  5. Women of (WOCBP) must be non-pregnant and must use an acceptable, highly effective from Screening until the study completion, including the follow-up period.
  6. Participants must have the ability and willingness to attend the necessary visits to the clinical research unit (CRU);
  7. Participants must be willing and able to provide written informed consent after the nature of the study has been explained and prior to the commencement of any study procedures.

Exclusion criteria

Exclusion Criteria:

A participant who meets any of the following exclusion criteria must be excluded from the study:

  1. Diagnosis of type 2 ( ≥6.5%) or other types of diabetes mellitus;
  2. Obesity induced by endocrine disorders (e.g., Cushing syndrome);
  3. Calcitonin ≥50 ng/L (pg/mL) at Screening;
  4. History of severe allergic or to any of the products or its or to drugs of similar chemical classes;
  5. History of cerebral stroke (including but not limited to cerebral infarction/haemorrhage) within 6 months prior to Screening;
  6. History of acute coronary syndrome (angina pectoris and/or myocardial infarction) and any other major cardiac conditions (including but not limited to myocarditis, cardiac insufficiency/failure, and any arrythmia[s]) within 6 months prior to Screening;
  7. Impaired liver function defined as (ALT) or aspartate aminotransferase (AST) >5 times (ULN) at Screening;

Main Inclusion Criteria:

To be eligible for this study, a participant has to meet all of the following inclusion criteria:

  1. Male or female, aged 18 to 70 years (inclusive at the time of );
  2. Participants must have a ≥ 30.0 kg/m2 and ≤40.0 kg/m2 at Screening;
  3. Participants must have stable body weight for at least 3 months prior to Screening (\<5% change, self-reported);
  4. Participants must have glycated hemoglobin (HbA1c) level \<6.5% at Screening;
  5. Women of (WOCBP) must be non-pregnant and must use an acceptable, highly effective from Screening until the study completion, including the follow-up period.
  6. Participants must have the ability and willingness to attend the necessary visits to the clinical research unit (CRU);
  7. Participants must be willing and able to provide written informed consent after the nature of the study has been explained and prior to the commencement of any study procedures.

Main Exclusion Criteria:

A participant who meets any of the following exclusion criteria must be excluded from the study:

  1. Diagnosis of type 2 (HbA1c ≥6.5%) or other types of diabetes mellitus;
  2. Obesity induced by endocrine disorders (e.g., Cushing syndrome);
  3. Calcitonin ≥50 ng/L (pg/mL) at Screening;
  4. History of severe allergic or hypersensitivity to any of the investigational products or its excipients or to drugs of similar chemical classes;
  5. History of cerebral stroke (including but not limited to cerebral infarction/haemorrhage) within 6 months prior to Screening;
  6. History of acute coronary syndrome (angina pectoris and/or myocardial infarction) and any other major cardiac conditions (including but not limited to myocarditis, cardiac insufficiency/failure, and any clinically significant arrythmia[s]) within 6 months prior to Screening;
  7. Impaired liver function defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >5 times upper limit of normal (ULN) at Screening;
  8. Estimated (eGFR), calculated using the modified diet in renal disease (MDRD) formula \< 60 mL/min/1.73m2;
  9. History of acute or chronic pancreatitis or defined as amylase >ULN at Screening;
  10. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2);
  11. Positive infection with human immunodeficient virus (), virus (HBV), or virus (HCV);
  12. History of primary or recurrent , except for non-melanoma skin cancer excised more than 2 years prior to Screening;
  13. History of clinically significant endocrine condition(s);
  14. History of major depressive disorder within 2 years before randomisation;
  15. History of surgical treatment for obesity;
  16. Having been exposed to any GLP-1 analogues within 6 months before Screening;
  17. Treatment with orlistat, zonisamide, topiramate, phentermine, lorcaserin, bupropion and naltrexone alone or in combination or any other medications that could promote weight loss within 90 days prior to Screening;
  18. Use of any other investigational products or medical devices within 3 months prior to Screening;
  19. Participation in any medical (e.g., assisted by a clinical dietician or nutritionist) or non-medical (e.g., by a gym coach) diet and/or exercise program within 3 months prior to Screening and for the duration of the study (including the follow-up period);
  20. Known or suspected abuse of alcohol or recreational drugs;
  21. Being pregnant or lactating at Screening or planning to become pregnant (self or female partner) at any time during the study and for at least 3 months after the last dose of study drug;
  22. Presence of any underlying physical and/or psychological medical condition that, in the opinion of the investigator, would make it unlikely that the participant will comply with the protocol or complete the study per protocol.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
206 participants (actual)

Study arms

  • Experimental
    Cohort A

    Participants will follow a fixed up-titration scheme. For XW003 groups, the dose will be up-titrated to 1.2, 1.8, or 2.4 mg once weekly starting with 0.2 mg in dose increments of 0.2, 0.4, 0.6, or 0.8 mg. In order to mitigate the dose-related side effects, liraglutide is up-titrated over 4 weeks to the maintenance dose, 3.0 mg once daily.

    Drug: XW003

  • Experimental
    Cohort B

    Participants will follow a fixed up-titration scheme. For XW003 groups, the dose will be up-titrated to 1.2, 1.8, or 2.4 mg once weekly starting with 0.2 mg in dose increments of 0.2, 0.4, 0.6, or 0.8 mg. In order to mitigate the dose-related side effects, liraglutide is up-titrated over 4 weeks to the maintenance dose, 3.0 mg once daily.

    Drug: XW003

  • Experimental
    Cohort C

    Participants will follow a fixed up-titration scheme. For XW003 groups, the dose will be up-titrated to 1.2, 1.8, or 2.4 mg once weekly starting with 0.2 mg in dose increments of 0.2, 0.4, 0.6, or 0.8 mg. In order to mitigate the dose-related side effects, liraglutide is up-titrated over 4 weeks to the maintenance dose, 3.0 mg once daily.

    Drug: XW003

  • Active comparator
    Cohort D

    Dose titration Saxenda (from 0.6 mg to 3.0 mg liraglutide once daily), should take place during the first 4 weeks after randomisation as described: Dose Escalation Schedule of Reference Product (Saxenda). All participants assigned to the open-labeled control group should aim to reach the final target dose of 3.0 mg liraglutide once daily.

    Drug: Saxenda

Interventions

  • DrugXW003

    XW003 (from 0.2 mg to 1.2 mg, 1.8 mg, and 2.4 mg once weekly), should take place during the first 14 weeks after randomization as described: Dose Escalation Schedule of Investigational Product (XW003). All eligible participants assigned to the XW003 study groups should aim to reach the respective final target dose of XW003 at 1.2 mg, 1.8 mg, or 2.4 mg once weekly.

    Also known as: GLP-1 analogue

  • If a participant does not tolerate the recommended target dose of Saxenda group (e.g., 3.0 mg once daily), the participant may stay at the preceding highest tolerable dose (e.g., 2.4 mg once daily).

    Also known as: GLP-1 analogue

06

What researchers measure

Primary outcomes

  1. Percentage change in participants body weight (%) from the Baseline

    Analysis of covariance (ANCOVA), with treatment, baseline body weight, and stratification factor as covariate, will be used to determine the difference between one of the XW003 groups and Saxenda group.

    Time frame: Week 26

Secondary outcomes

  1. Proportions of participants with body weight loss ≥5%, ≥10% and ≥15% of the Baseline

    It is anticipated that XW003 can achieve considerable body weight loss and improve obesity-related markers in participants with obesity.

    Time frame: Week 26

  2. Absolute change in body weight (kg) of participants

    Body weight should be measured at all site visits without shoes, on an empty bladder and only wearing light clothing.

    Time frame: Week 26

  3. Changes in waist circumference and hip circumference (cm) in participants

    The waist circumference will be measured at the specified visits and is defined as the abdominal circumference located the midpoint between the lower rib margin and the iliac crest. The hip circumference is defined as the widest circumference around the buttocks.

    Time frame: Week 26

  4. Change in BMI in participants

    Calculated by dividing the participant's body weight in kilograms by the participant's height in meters squared (kg/m2)

    Time frame: Week 26

  5. Change in fasting plasma glucose (FPG)

    Calculated based on XW003 measured in blood.

    Time frame: Week 26

  6. Change in fasting serum insulin

    Calculated based on XW003 measured in blood.

    Time frame: Week 26

  7. Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

    Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

    Time frame: Week 26

  8. Changes in fasting lipids (triglyceride, low-density lipoprotein [LDL], and high-density lipoprotein [HDL])

    Lipids: triglyceride, low-density lipoprotein \[LDL\], and high-density lipoprotein \[HDL\].

    Time frame: Week 26

  9. Number and severity of treatment-emergent adverse events (TEAEs)

    The most common treatment-emergent adverse events (TEAEs) were nausea, dyspepsia, constipation, vomiting, and loss of appetite, all of which deemed possibly related to XW003 injection and only occurred in the highest dose groups (0.6 mg and 1.0 mg). The severity of these TEAEs was mild or moderate.

    Time frame: Week 26

  10. Number and severity of new and ongoing gastrointestinal (GI) disorder (nausea, vomiting, diarrhea, and constipation) events by week

    Analysis of the safety profile and tolerability of XW003 showed that the most common adverse events (AEs) of XW003 was gastrointestinal (GI) disorder, including nausea, bloating, loss of appetite, and weight loss.

    Time frame: Week 26

  11. Vital signs - participants' blood pressure change

    After resting in a supine position for at least 5 minutes, the participant's systolic and diastolic blood pressure change.

    Time frame: Week 26

  12. Vital signs - participants' pulse rate change

    After resting in a supine position for at least 5 minutes, the participant's pulse rate, and body temperature.

    Time frame: Week 26

  13. Vital signs - participants' ody temperature change

    After resting in a supine position for at least 5 minutes, the participant's body temperature change.

    Time frame: Week 26

  14. Electrocardiograms (ECGs)

    There was no XW003 injection related clinically significant effect 12-lead electrocardiography (ECG).

    Time frame: Week 26

  15. Haematology, biochemistry, coagulation, and calcitonin

    Parameters to be tested are: * Haemoglobin (HGB) * Haematocrit (HCT) * Erythrocytes (RBC) * Platelets (PLAT) * Leucocytes (WBC) with differential * Urea * Creatinine (CREAT) * Total Bilirubin (BILI) and direct bilirubin (BILIDIR) * Urate * Albumin (ALB) * Alkaline phosphatase (ALP) * Creatine kinase (CK) * Alanine aminotransferase (ALT) * Aspartate aminotransferase (AST) * Gamma-glutamyl transferase (GGT) * Sodium (NA) * Potassium (K) * Calcium (CA) * Chloride (CL) * Phosphate (PHOS) * Bicarbonate (BICARB) * Amylase * Lipase * International Normalised Ratio (INR) * Activated partial thromboplastin time (APTT)

    Time frame: Week 26

  16. Injection site reactions (ISRs)

    There were no hypoglycaemic episodes reported during the trial. Injection site reaction (ISRs) were reported in 1 participant in Cohort A2 (0.2/0.25 mg) and 2 participants in Cohort A6 (0.6 mg). The ISRs were mild in severity and recovered within 3 hours of dosing.

    Time frame: Week 26

  17. Physical examinations

    It should include general appearance, thyroid gland, respiratory system, cardiovascular system, gastrointestinal system including mouth, musculoskeletal system, central and peripheral nervous system, skin, lymph node palpation, and head, ears, eyes, nose, throat and neck.

    Time frame: Week 26

  18. 36-Item Short Form Survey (SF-36)

    Physical and mental component summary scores and scores on the individual sub-domains, i.e., physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health

    Time frame: Week 26

Other outcomes

  1. Plasma concentrations of XW003 on treatment

    Calculated based on XW003 measured in blood.

    Time frame: Week 26

  2. Anti-XW003 antibodies on treatment

    Calculated based on XW003 measured in blood.

    Time frame: Week 26

07

Study locations

1 site
  • Paratus Clinical Research Brisbane
    Brisbane, Queensland 4010, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Nov 2022, 11 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 11 months is close to that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2021
First posted
Nov 8, 2021
StartActual
Nov 30, 2021
Primary completionActual
Nov 16, 2022
CompletionActual
Dec 20, 2022
Last update
Aug 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05111912
Lead sponsor
Sciwind Biosciences APAC CO Pty. Ltd.
Collaborators
Hangzhou Sciwind Biosciences Co., Ltd.
Responsible party
Sponsor
First posted
Nov 8, 2021
Start date
Nov 30, 2021
Primary completion
Nov 16, 2022
Completion
Dec 20, 2022
Last update
Aug 21, 2023

Study contacts

Sheetal Bull
principal investigator · Paratus Clinical

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ecnoglutide

Start the discussion